City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...


Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
San Antonio bioscience company Xenex secures major funding
January 27, 2015

U.S. Air Force Hospital Langley recently received a germ-zapping robot from Xenex Disinfection Services that can disinfect a room from bacteria and viruses in five to 10 minutes, company officials said. (Photo by Joe Fudge)

By W. Scott Bailey, San Antonio Business Journal

Xenex Disinfection Services has secured $25 million in new funding from multiple investors. The San Antonio-based company, which has seen increased interest among health care facilities for its robotic germ-zapping device, will use the new capital to fund product development, international expansion and a larger sales force.

Xenex officials said decreased reimbursements and increased scrutiny for hospitals dealing with health care-associated infections have driven up demand for the company's patented pulsed xenon device, which eliminates deadly microorganisms that can cause serious hospital-acquired infections, or HAIs. Concerns about the spread of Ebola have further fueled demand for the device.

"Hospital-acquired infections are a global problem, and we have proven that the use of our germ-zapping robot provides a cleaner, and therefore safer health care environment," Xenex CEO Morris Miller said in a news release.

In October Miller told me, "The arrival of Ebola in the U.S. has served as a wake-up call for our hospitals and the (Centers for Disease Control and Prevention) that current infection-prevention efforts aren't enough. There's been a significant spike in interest for our germ-zapping robots."

Some of the latest Xenex funding comes from a new investor - Brandon Point Industries Ltd., a life sciences company based in Ireland. The balance is from current Xenex investors, including Battery Ventures, Targeted Technology Fund II and RK Ventures.

Brandon Point co-founder Kelly Martin said Xenex's unique technology addresses "important and immediate patient and health care worker needs" at a time when there are growing concerns about "worldwide disease outbreaks."

Xenex's robotic device can disinfect hospital rooms and other medical areas in a matter of minutes, company officials said. More than 250 hospitals and Veterans Affairs and Department of Defense facilities in the U.S. are using Xenex robots.

Stay informed. Subscribe to BioMed SA news alerts.